HUTCHMED (China) Limited (previously Chi-Med) is set to lead Chinese biotechs' latest fundraising rounds in June.
HutchMed announced on 18 June that it is looking to raise up to HKD4.7bn ($602.8m) in an initial public offering...
HutchMed Set to Lead China Biotech Fundraising In June
PE Also Strong
Listen to this article
The China-based biopharma company is seeking up to $602.8m gross in its Hong Kong IPO.
Keep up with the top pharma business news of the week. On the go.
More from Financing
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
• By
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
More from Business
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.